Literature DB >> 15066434

Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope.

Alfredo Menendez1, Keith C Chow, Oscar C C Pan, Jamie K Scott.   

Abstract

Human monoclonal antibody 2F5 is one of a few human antibodies that neutralize a broad range of HIV-1 primary isolates. The 2F5 epitope on gp41 includes the sequence ELDKWA, with the core residues, DKW, being critical for antibody binding. HIV-neutralizing antibodies have never been elicited by immunization with peptides bearing ELDKWA, suggesting that important part(s) of the 2F5 paratope remain unidentified. The use of longer peptides extending beyond ELDKWA has resulted in increased epitope antigenicity, but neutralizing antibodies have not been generated. We sought to develop peptides that bind to 2F5, and that function as specific probes of the 2F5 paratope. Thus, we used 2F5 to screen a set of phage-displayed, random peptide libraries. Tight-binding clones from the random peptide libraries displayed sequence variability in the regions flanking the DKW motif. To further reveal flanking regions involved in 2F5 binding, two semi-defined libraries were constructed having 12 variegated residues either N-terminal or C-terminal to the DKW core (X(12)-AADKW and AADKW-X(12), respectively). Three clones isolated from the AADKW-X(12) library had similar high affinities, despite a lack of sequence homology among them, or with gp41. The contribution of each residue of these clones to 2F5 binding was evaluated by Ala substitution and amino acid deletion studies, and revealed that each clone bound 2F5 by a different mechanism. These results suggest that the 2F5 paratope is formed by at least two functionally distinct regions: one that displays specificity for the DKW core epitope, and another that is multispecific for sequences C-terminal to the core epitope. The implications of this second, multispecific region of the 2F5 paratope for its unique biological function are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15066434     DOI: 10.1016/j.jmb.2004.02.051

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  24 in total

1.  Developing strategies to enhance and focus humoral immune responses using filamentous phage as a model antigen.

Authors:  Kevin A Henry; Armstrong Murira; Nienke E van Houten; Jamie K Scott
Journal:  Bioeng Bugs       Date:  2011-09-01

2.  Stoichiometry of murine leukemia virus envelope protein-mediated fusion and its neutralization.

Authors:  Wu Ou; Jonathan Silver
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

3.  Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

Authors:  Michael B Zwick; Richard Jensen; Sarah Church; Meng Wang; Gabriela Stiegler; Renate Kunert; Hermann Katinger; Dennis R Burton
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 4.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

5.  Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: implications for antibody recognition mechanism and immunogen design.

Authors:  Soraya Serrano; Aitziber Araujo; Beatriz Apellániz; Steve Bryson; Pablo Carravilla; Igor de la Arada; Nerea Huarte; Edurne Rujas; Emil F Pai; José L R Arrondo; Carmen Domene; María Angeles Jiménez; José L Nieva
Journal:  J Biol Chem       Date:  2014-01-15       Impact factor: 5.157

Review 6.  Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies.

Authors:  F Benjelloun; P Lawrence; B Verrier; C Genin; S Paul
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

7.  Engineering filamentous phage carriers to improve focusing of antibody responses against peptides.

Authors:  Nienke E van Houten; Kevin A Henry; George P Smith; Jamie K Scott
Journal:  Vaccine       Date:  2010-01-05       Impact factor: 3.641

8.  Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide.

Authors:  N E van Houten; M B Zwick; A Menendez; J K Scott
Journal:  Vaccine       Date:  2006-01-11       Impact factor: 3.641

9.  The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.

Authors:  Nerea Huarte; Maier Lorizate; Rubén Maeso; Renate Kunert; Rocio Arranz; José M Valpuesta; José L Nieva
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

10.  A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120.

Authors:  Alfredo Menendez; Daniel A Calarese; Robyn L Stanfield; Keith C Chow; Chris N Scanlan; Renate Kunert; Herman Katinger; Dennis R Burton; Ian A Wilson; Jamie K Scott
Journal:  FASEB J       Date:  2008-01-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.